Agfa-Gevaert
(Article 14 of the law of May 2, 2007 on the disclosure of significant shareholdings)
Mortsel, Belgium – March 12, 2021 – 5.40 p.m. CET
According to Agfa-Gevaert NV’s bylaws, the threshold as from which a shareholding needs to be disclosed, has been set at 3%, 5% and a multiple of 5%.
In conformity with the Law of May 2, 2007 regarding the disclosure of significant shareholdings in listed companies, Agfa-Gevaert (Euronext: AGFB) discloses the following declarations:
Norges Bank has announced on March 11, 2021, that it held a stake in
Agfa-Gevaert as per March 9, 2021 of 4,425,372 voting rights or 2.58% (denominator is 171,851,042), thus remaining under the threshold of 3%. At the same time Norges Bank declared to have 729,358 voting rights or 0.42% on loan. This gives a total of 5,154,730 voting rights or 3.00%.
Norges Bank is the central bank of Norway. As part of its central bank activities, Norges Bank manages Norway's foreign exchange reserves and is responsible for the management of the Norwegian Government Pension Fund Global (GPFG). The formal responsibility for the management of the GPFG is placed with the Ministry of Finance, but is delegated to Norges Bank. All investments are executed by Norges Bank acting as principal and all holdings are registered in the name of Norges Bank.
Notifications of important shareholdings to be made according to the Law of
May 2, 2007 or Agfa-Gevaert NV’s bylaws, should be sent to viviane.dictus@agfa.com and johan.jacobs@agfa.com.
About Agfa
The Agfa-Gevaert Group is a leading company in imaging technology and IT solutions with over 150 years of experience. The Group holds four divisions: Radiology Solutions, HealthCare IT, Digital Print & Chemicals and Offset Solutions. They develop, manufacture and market analogue and digital systems for the healthcare sector, for specific industrial applications and for the printing industry. In 2020, the Group realized a turnover of 1,709 million Euro.
Contact:
Viviane Dictus
Director Corporate Communications
tel. ++32 0 3 444 7124
e-mail: viviane.dictus@agfa.com
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Teva Pharmaceutical Industries Ltd16.9.2025 22:30:00 CEST | Press release
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting
Society of Actuaries16.9.2025 20:46:16 CEST | Press release
Society of Actuaries Announces Planned CEO Succession in 2026
Lehman Brothers UK Capital Funding LP16.9.2025 17:53:36 CEST | Press release
Lehman Brothers UK Capital Funding LP: Notice of Proposed Interim Payment
Sampo plc16.9.2025 17:10:00 CEST | Press release
Sampo prices the issuance of new Restricted Tier 1 notes
Ringkjøbing Landbobank A/S16.9.2025 17:00:58 CEST | Pressemeddelelse
Ringkjøbing Landbobank udsteder Tier 2-kapital
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom